The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The future may be getting brighter in terms of reducing the threat of ...

Solving HIV vaccination—a puzzle that scientists have been tackling for decades without success—could be like cracking the code to a safe. The key, they now think, may be delivering a series of ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year. Gilead Sciences, GSK, ViiV Healthcare 1 to 3 years In June 2024, results from a trial ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and ...

SEATTLE – October 27, 2025 –Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they ...

Mike McCune, MD, PhD, head of the HIV Frontiers Program at the Gates Foundation, delivered an upbeat message at the ASGCT annual conference in New Orleans last week, showcasing the progress being made ...

Experts are expressing relief that the US President’s Emergency Plan for AIDS Relief (PEPFAR), a $7.5 billion program credited with saving 26 million lives around the world from HIV, was spared ...